

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
08 August 2019 (08.08.2019)



(10) International Publication Number
WO 2019/152705 A1

(51) International Patent Classification:
C07K 16/28 (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/US2019/016139

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))

(22) International Filing Date:
31 January 2019 (31.01.2019)

Published:

— with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/625,019 01 February 2018 (01.02.2018) US
62/641,873 12 March 2018 (12.03.2018) US

(71) Applicant: **PFIZER INC.** [US/US]; 235 East 42nd Street,
New York, New York 10017 (US).

(72) Inventors: **PANOWSKI, Siler**; c/o Pfizer Inc., 235 East
42nd Street, New York, New York 10017 (US). **SAI, Tao**;
c/o Pfizer Inc., 235 East 42nd Street, New York, New
York 10017 (US). **SASU, Barbra Johnson**; c/o Pfizer Inc.,
235 East 42nd Street, New York, New York 10017 (US).
SRIVATSA SRINIVASAN, Surabhi; c/o Pfizer Inc., 235
East 42nd Street, New York, New York 10017 (US). **VAN**
BLARCOM, Thomas John; c/o Pfizer Inc., 235 East 42nd
Street, New York, New York 10017 (US).

(74) Agent: **WHITTLE, James R. R.** et al.; Cooley LLP, 1299
Pennsylvania Avenue, NW, Suite 700, Washington, District
of Columbia 20004-2400 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: ANTIBODIES SPECIFIC FOR CD70 AND THEIR USES

(57) Abstract: The present invention provides antibodies that specifically bind to CD70 (Cluster of Differentiation 70). The invention further provides bispecific antibodies that bind to CD70 and another antigen (e.g., CD3). The invention further relates to antibody encoding nucleic acids, and methods of obtaining such antibodies (monospecific and bispecific). The invention further relates to therapeutic methods for use of these antibodies for the treatment of CD70-mediated pathologies, including cancer.

WO 2019/152705 A1